Alnylam Assist™: Support for Every Step

 
Hi, I’m Natalie

Your Dedicated Case Manager

I'm here to support you throughout your treatment experience and have been specifically assigned to help you with questions you may have about Alnylam Assist™ and AMVUTTRA™.

Call Natalie:

1-833-256-2748

Monday - Friday,
8am - 6pm ET

Get Started

How We Can Help

Now that you or your loved one has been diagnosed with the polyneuropathy of hATTR amyloidosis and prescribed AMVUTTRA™ (vutrisiran), Alnylam Assist™ is here to help support you.

Each person is unique—your support should be that way, too. Alnylam Assist™ is designed to be truly personalized: a support team who is easily accessible and adaptable. So if your support needs change during treatment, your level of support can change, too.

How We Can Help

Get the Support You Need

After you begin treatment with AMVUTTRA and enroll in Alnylam Assist™, your dedicated Case Manager and the Alnylam Assist™ team will provide ongoing support in 3 key areas:

Alnylam Assist® - Understanding Your Benefits
Understanding Your Benefits

Review and verify your insurance benefit coverage for AMVUTTRA treatment.

Alnylam Assist™ - Financial Assistance Options
Financial Assistance Options

Alnylam Assist™ provides financial assistance options for qualifying individuals. Your Case Manager will work with you to determine eligibility.*

*  Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Alnylam Assist® - Disease And Treatment Education
Disease and Treatment Education

Materials to help educate you and your family on hATTR amyloidosis and treatment.

Support for Your Journey

In addition to personalized support from your Case Manager, Alnylam Assist™ can help educate you and your loved ones about hATTR amyloidosis and connect you with advocacy organizations that are involved in the hATTR amyloidosis community.

See More Resources

Our Message to Caregivers

Alnylam Assist™ Caregiver Support Icon

We're here to support you while you support your loved ones

We understand that support is more than insurance, and that you can be affected by the polyneuropathy of hATTR amyloidosis, too. Alnylam Assist™ is here to help you navigate the day-to-day treatment experience, while you navigate everything else. Don't worry, you're in the right place.

See More Resources

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with AMVUTTRA, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Natalie

Call Natalie

1-833-256-2748

Monday - Friday,
8am - 6pm ET

Alylam Separator Triangles

IMPORTANT SAFETY INFORMATION

What are the most important things I should know about AMVUTTRA?

AMVUTTRA can cause:

Low Vitamin A Levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATION

What is AMVUTTRA™ (vutrisiran)?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin‑mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.